Supersuppressive Induced Regulatory T-Cell Populations
Abstract
This proposal is directly focused on studies that leverage immunological approaches to prevent and treat inflammatory bowel disease (IBD). IBD is a more encompassing term that includes two more widely recognized diagnoses: ulcerative colitis (UC) and Crohn's disease CD). The number of both diagnoses are increasing. To date, there is no cure for IBD. Immune regulation of the gut is extremely complex. The gastrointestinal immune system must maintain the dexterity to both maintain tolerance towards food and the commensal microflora while mounting a rapid response against pathogens. It is the primary responsibility of regulatory T cells to maintaining this critical equilibrium. This capacity to maintain/restore balance establish regulatory T cells as the master regulators of intestinal balance. In fact, numerous animal studies have identified regulatory T cell deficiency as an important contributor to IBD. However, the central critical question to be addressed is: what is the exact regulatory T cell phenotype critical for immune regulation and therefore appropriate for IBD treatment remains unresolved? This proposal utilizes a proprietary combination of novel bio-inspired protein mimics to easily and effectively deliver antibodies intracellularly to CD4 T cells. The development of a stable, rapidly expandable, super-suppressive regulatory T cell phenotype will find widespread application in IBD.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1196244
Entities
People
- Gregory N Tew
Organizations
- University of Massachusetts Amherst